Einzeltreffer — DigiBib

Background: Despite histological and molecular differences between invasive lobular carcinoma (ILC) and invasive carcinoma of no special type, according to national treatment guidelines no distinction is made regarding the use of (neo)adjuvant chemotherapy. Studies on the long-term outcome of chemotherapy in patients with ILC are scarce and show inconclusive results.

Methods: All patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative ILC with an indication for chemotherapy treated with adjuvant endocrine therapy were selected from the Erasmus Medical Center Breast Cancer database. Cox proportional hazards models were used to estimate the effect of chemotherapy on recurrence-free survival (RFS), breast cancer-specific survival (BCSS), and overall survival (OS).

Results: A total of 520 patients were selected, of whom 379 were treated with chemotherapy and 141 were not. Patients in the chemotherapy group were younger (51 vs. 61 years old; p < .001), had a higher T status (T3+, 33% vs. 14%; p < .001), and more often had lymph node involvement (80% vs. 49%; p < .001) in comparison to the no-chemotherapy group. After adjusting for confounders, chemotherapy treatment was not associated with better RFS (hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.63-2.31), BCSS (HR, 1.24; 95% CI, 0.60-2.58), or OS (HR, 0.97; 95% CI, 0.56-1.66). This was also reflected by adjusted Cox survival curves in the chemotherapy versus no-chemotherapy group for RFS (75% vs. 79%), BCSS (80% vs. 84%), and OS (72% vs. 71%).

Conclusions: Chemotherapy is not associated with improved RFS, BCSS, or OS for patients with ER+/HER2- ILC treated with adjuvant endocrine therapy and with an indication for chemotherapy.

Titel:	The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.
Autor/in / Beteiligte Person:	Öztekin, S ; Hooning, MJ ; van Deurzen CHM ; Dietvorst, AHP ; Drooger, JC ; Kitzen, JJEM ; Martens, JWM ; van der Padt-Pruijsten A ; Vastbinder, MB ; Zuetenhorst, H ; Heemskerk-Gerritsen, BAM ; Jager, A
Link:	Full Text Finder (Volltext)
Zeitschrift:	Cancer, Jg. 130 (2024-03-15), Heft 6, S. 927-935
Veröffentlichung:	<2005- >: Hoboken, NJ : Wiley ; <i>Original Publication</i>: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.], 2024
Medientyp:	academicJournal
ISSN:	1097-0142 (electronic)
DOI:	10.1002/cncr.35125
Schlagwort:	Humans Middle Aged Female Retrospective Studies Breast pathology Chemotherapy, Adjuvant Receptor, ErbB-2 metabolism Adjuvants, Immunologic Immunologic Factors therapeutic use Breast Neoplasms pathology Carcinoma, Lobular drug therapy Carcinoma, Lobular pathology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Cancer] 2024 Mar 15; Vol. 130 (6), pp. 927-935. <i>Date of Electronic Publication: </i>2023 Nov 20. MeSH Terms: Breast Neoplasms* / pathology ; Carcinoma, Lobular* / drug therapy ; Carcinoma, Lobular* / pathology ; Humans ; Middle Aged ; Female ; Retrospective Studies ; Breast / pathology ; Chemotherapy, Adjuvant ; Receptor, ErbB-2 / metabolism ; Adjuvants, Immunologic ; Immunologic Factors / therapeutic use References: Azzopardi JG, Chepick OF, Hartmann WH, et al. The World Health Organization histological typing of breast tumors-second edition. Am J Clin Pathol. 1982;78(6):806-816. ; Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73(6):1673-1677. doi:10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co;2-b. ; Christgen M, Steinemann D, Kühnle E, et al. Lobular breast cancer: clinical, molecular and morphological characteristics. Pathol Res Pract. 2016;212(7):583-597. doi:10.1016/j.prp.2016.05.002. ; Chen Z, Yang J, Li S, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One. 2017;12(9):e0182397. doi:10.1371/journal.pone.0182397. ; Desmedt C, Zoppoli G, Sotiriou C, Salgado R. Transcriptomic and genomic features of invasive lobular breast cancer. Semin Cancer Biol. 2017;44:98-105. doi:10.1016/j.semcancer.2017.03.007. ; Ciriello G, Gatza ML, Beck AH, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163(2):506-519. doi:10.1016/j.cell.2015.09.033. ; Mamtani A, King TA. Lobular breast cancer: different disease, different algorithms? Surg Oncol Clin N Am. 2018;27(1):81-94. doi:10.1016/j.soc.2017.07.005. ; de Nonneville A, Jauffret C, Gonçalves A, et al. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Res Treat. 2019;175(2):379-387. doi:10.1007/s10549-019-05160-9. ; Watanuki R, Hayashida T, Yokoe T, et al. Impact of neoadjuvant and adjuvant chemotherapy on invasive lobular carcinoma: a propensity score-matched analysis of SEER data. Breast J. 2020;26(9):1765-1770. doi:10.1111/tbj.13884. ; O'Connor DJ, Davey MG, Barkley LR, Kerin MJ. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-a systematic review and meta-analysis. Breast. 2022;61:1-10. doi:10.1016/j.breast.2021.11.017. ; Straver ME, Rutgers EJT, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411-2418. doi:10.1245/s10434-010-1008-1. ; Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29(4):361-367. doi:10.1053/ejso.2002.1404. ; Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41-48. doi:10.1200/jco.2005.03.111. ; Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17(8):1228-1233. doi:10.1093/annonc/mdl114. ; Truin W, Vugts G, Roumen RM, et al. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. 2016;23(1):51-57. doi:10.1245/s10434-015-4603-3. ; Loibl S, Volz C, Mau C, et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1):153-162. doi:10.1007/s10549-014-2861-6. ; Marmor S, Hui JYC, Huang JL, et al. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer. 2017;123(16):3015-3021. doi:10.1002/cncr.30699. ; Truin W, Voogd AC, Vreugdenhil G, van der Heiden-van der Loo M, Siesling S, Roumen RM. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol. 2012;23(11):2859-2865. doi:10.1093/annonc/mds180. ; International Classification of Diseases for Oncology (ICD-O-3). World Health Organization; 2000. ; Borstkanker-Adjuvante Systemische Therapie. Federatie Medisch Specialisten. Updated December 3, 2021. Accessed January 7, 2022. https://richtlijnendatabase.nl/gerelateerde_documenten/f/22762/Borstkanker%20-%20Adjuvante%20systemische%20therapie.pdf. ; van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. doi:10.1056/nejmoa021967. ; Abel MK, Shui AM, Chien AJ, et al. The 21-gene recurrence score in clinically high-risk lobular and ductal breast cancer: a National Cancer Database study. Ann Surg Oncol. 2022;29(12):7739-7747. doi:10.1245/s10434-022-12065-3. ; Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511-1522. doi:10.1093/jnci/djac157. ; Lips EH, Mukhtar RA, Yau C, et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012;136(1):35-43. doi:10.1007/s10549-012-2233-z. ; Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40(3):342-351. doi:10.1016/j.ejca.2003.08.015. Contributed Indexing: Keywords: chemotherapy; lobular breast cancer; retrospective; survival Substance Nomenclature: EC 2.7.10.1 (Receptor, ErbB-2) ; 0 (Adjuvants, Immunologic) ; 0 (Immunologic Factors) Entry Date(s): Date Created: 20231120 Date Completed: 20240226 Latest Revision: 20240311 Update Code: 20240312

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.